 |
|
Better Outcomes for Patients Treated at Hospitals That Participate in Clinical Trials
Sumit R. Majumdar, MD, MPH;
Matthew T. Roe, MD, MHS;
Eric D. Peterson, MD, MPH;
Anita Y. Chen, MS;
W. Brian Gibler, MD;
Paul W. Armstrong, MD
Arch Intern Med. 2008;168(6):657-662.
Background Barriers to institutions participating in clinical trials include concerns about harms and costs. However, we hypothesized that patients treated at hospitals participating in trials would have better outcomes than patients treated at nonparticipating hospitals. We tested this hypothesis in 494 CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) hospitals treating 174 062 patients with non–ST-segment elevation acute coronary syndrome.
Methods Hospitals were classified into tertiles by percentage of patients concurrently enrolled in non–ST-segment elevation acute coronary syndrome trials. Outcomes were use of composite guideline-indicated care and in-hospital mortality. Multivariate regression was used to examine the association between hospital trial participation and outcomes.
Results Overall, 4590 patients (2.6%) were enrolled in trials, ranging from 0% (145 hospitals) to low-enrollment tertile (1.0%; interquartile range [IQR], 0.5%-1.4%; n = 226) to high-enrollment tertile (4.9%; IQR, 3.5%-9.7%; n = 123). The composite guideline adherence score increased with increasing tertiles of trial participation: 76.9% (IQR, 71.8%-81.3%) vs 78.3% (IQR, 73.2%-82.4%) vs 81.1% (IQR, 76.2%-84.1%) (adjusted P = .008). Hospitals that participated in trials had higher adjusted guideline adherence than nonparticipating hospitals (low enrollment, 0.8% greater [95% confidence interval {CI}, –0.9% to 2.6%]; and high enrollment, 2.5% greater [95% CI, 0.5%-4.5%]). In-hospital mortality decreased with increasing trial participation: 5.9% vs 4.4% vs 3.5% (adjusted P = .003). Patients treated at hospitals that participated in trials had significantly lower mortality than patients treated at nonparticipating hospitals (low enrollment adjusted odds, 0.9 [95% CI, 0.8-1.0]; and high enrollment adjusted odds, 0.8 [95% CI, 0.7-0.9]).
Conclusions The CRUSADE hospitals enrolled less than 3% of their patients with non–ST-segment elevation acute coronary syndrome into trials, and one-third never participated in trials. Compared with hospitals that do not participate in trials, those hospitals that do participate in trials seem to provide better care and to have lower mortality.
Author Affiliations: Department of Medicine, University of Alberta, Edmonton, Alberta, Canada (Drs Majumdar and Armstrong); Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina (Drs Roe and Peterson and Ms Chen); and Department of Emergency Medicine, University of Cincinnati School of Medicine, Cincinnati, Ohio (Dr Gibler).
|
